The Baruch S. Blumberg Institute, a non-profit biomedical research organization, was awarded a $32,348,261 cost-plus-fixed-fee contract from the National Institute of Allergy and Infectious Diseases (NIAID) to develop an orally available small molecule antiviral drug for the treatment of yellow fever virus infection. This multi-year project will be performed in collaboration with subcontractor Utah State University. The contract was awarded under a Broad Agency Announcement (BAA) from NIAID that sought proposals for the development of vaccines, therapeutics, and diagnostics for biodefense, antimicrobial resistant infections, and emerging infectious diseases. No set-aside designation was used for this contract award.
Generated 1/15/25, 9:32 AM